Please make a donation to the Aplastic Anemia and MDS International Foundation this holiday season.
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer
For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer.
November 2021 – Lung Cancer
Laura Morgan
Link above leads to podcast recording.
Dr. Andrew Brunner is an Assistant Professor, Medicine at Harvard Medical School and Assistant in Medicine at the Center for Leukemia at Massachusetts General Hospital in Boston, Massachusetts. His research is focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. He is involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.
Dr. Eric Yang is currently an Associate Clinical Professor of Medicine at the Ronald Reagan University of California, Los Angeles Medical Center. He obtained his undergraduate and medical degrees at the University of Illinois at Chicago College of Medicine, and completed his internal medicine residency and cardiology fellowship at Harbor-UCLA Medical Center, where he served as chief fellow.
Anthony M. Hunter, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A hematologist, Dr.
“Your blood counts are nearly nonexistent,” the doctor said.
Before this moment, Debra considered herself to be generally healthy, just tiring easily. She assumed the cause was the big project at work on top of a host of family and volunteer activities, or perhaps issues with her blood pressure. It was autumn of 2017.
Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang joined the Roswell Park faculty in 2003 and was appointed to the Leukemia Service of the Department of Medicine. She earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY.
When a child is diagnosed with a bone marrow failure disease, often the focus is soley on the child's medical care.
As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of